OS Benefit Modest or Absent With Many High-Cost Therapies Approved for GI Malignancies
Investigators assessed disparities in patient access to therapies approved for the treatment of gastrointestinal malignancies in the United States, the United Kingdom, Europe, and Ireland, as well as benefit relative to cost.